Results 131 to 140 of about 208,685 (341)

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou, Yu Wu, Guoran Li, Yongwen Qin, Man Qi, Zhitao Jin   +5 more
wiley   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Understanding longitudinal bi-ventricular structural and functional changes in a Pulmonary Hypertension Sugen-Hypoxia rat model by Cardiac Magnetic Resonance Imaging [PDF]

, 2020
Buist, Hanna, Church, A. Colin, Gallagher, Lindsay, Holmes, William M., Hughes, Colin, Jayasekera, Geeshath, Johnson, Martin K., MacLean, Mandy R., Mullin, James, Nilsen, Margaret, Peacock, Andrew J., Uckan, Aysel, Welsh, David J., Wilson, Kathryn S., Woodward, Rosemary   +14 more
core   +2 more sources

685 Left Ventricular index of stiffness- a potential mechanism for differentiating hyperrtrophic cardiomyopathy and left ventricular hypertrophy [PDF]

, 2006
Gehad A Abdalla
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Western Diet-Fed, Aortic-Banded Ossabaw Swine: A Preclinical Model of Cardio-Metabolic Heart Failure. [PDF]

, 2019
The development of new treatments for heart failure lack animal models that encompass the increasingly heterogeneous disease profile of this patient population.
Alex, Linda, Baines, Christopher P, Domeier, Timothy L, Edwards, Jenna C, Emter, Craig A, Ferreira-Nichols, Stephanie C, Ford, David A, Gao, Chen, Ivey, Jan R, Jones, John L, Jurrissen, Thomas J, Klutho, Paula J, Krenz, Maike, McDonald, Kerry S, Olver, T Dylan, Padilla, Jaume, Rau, Christoph, Rector, R Scott, Solaro, R John, Thorne, Pamela K, Veteto, Adam B, Wang, Yibin, Warren, Chad M   +22 more
core  

Alterations in the expression of genes related to contractile function and hypertrophy of the left ventricle in chronically paced patients from the right ventricular apex (preliminary results) [PDF]

, 2013
Εmmanuel Simantirakis, I. Kontaraki, E. G. Arkolaki, Stavros I. Chrysostomakis, Alexandros Patrianakos, Panos E. Vardas   +5 more
openalex   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Moexipril and left ventricular hypertrophy

Vascular Health and Risk Management, 2007
George S Chrysant1, PK NguyenUniversity of Oklahoma, 1Director, Advanced Cardiac Imaging, INTEGRIS Heart Hospital, Oklahoma City, OK, USAAbstract: Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy of patients with myocardial ...
George S Chrysant, PK Nguyen
doaj  

LEFT VENTRICULAR HYPERTROPHY IN TERMS OF SUDDEN CARDIAC DEATH

, 2023
А. В. Барсуков, E. V. Borisova, М.С. Диденко, С.А. Глебова, Армен Владимирович Айрапетян, М.Л. Лигидов, S. D. Rud, Е.И. Асатурова, И.И. Коновалова   +8 more
openalex   +2 more sources